10 results on '"Romani, C."'
Search Results
2. Cluster of Cases of Salmonella enterica Serotype Rissen Infection in a General Hospital, Italy, 2007 T. Boschi et al. Salmonella enterica Serotype Rissen Infection.
- Author
-
Boschi, T., Aquilini, D., Degl'Innocenti, R., Aleo, A., Romani, C., Nicoletti, P., Buonomini, M. I., Marconi, P., Bilei, S., Mammina, C., and Nastasi, A.
- Subjects
SALMONELLA ,SEROTYPES ,DIAGNOSTIC microbiology ,ENTERITIS ,EPIDEMIOLOGICAL research ,PULSED-field gel electrophoresis ,COMMUNITY-acquired infections - Abstract
In 2007, three strains of Salmonella enterica serotype Rissen ( S. Rissen) were isolated in the laboratory of diagnostic microbiology of the General Hospital of Prato, Tuscany, Italy, over a 1 month and half interval of time. The first isolate was recovered on January 26 from an outpatient with enteritis. Then, two strains were isolated on February 16 and March 11 respectively, from central venous catheters of patients who were being hospitalized in two departments of the Hospital. An epidemiologically linked cluster of cases of salmonellosis was suspected. The three strains were submitted to single enzyme-amplified fragment length polymorphism (SE-AFLP) and XbaI macrorestriction and pulsed-field gel electrophoresis (PFGE) that yielded undistinguishable profiles. Epidemiological investigations failed to identify a common source of infection within the Hospital. Moreover, the third patient had been exclusively total parenteral nutrition fed since his admission with a stomach cancer diagnosis. The first patient had a community-acquired infection, but the source of her illness was uncertain. Twenty-five further isolates identified in the years 2004-2007 in the same geographical area showed distinctly different PFGE and SE-AFLP patterns. The three patients seemed to represent a cluster of epidemiologically unrelated cases caused by a previously never recognized S. Rissen strain. Rapid subtyping of isolates is essential in the early investigation of potential outbreaks, but synthesis of conventional and molecular epidemiological investigation and availability of surveillance data is often critical to prevent the initiation of time-consuming, expensive and ineffective further investigations and control interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
3. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study.
- Author
-
Candoni A, Lazzarotto D, Ferrara F, Curti A, Lussana F, Papayannidis C, Del Principe MI, Bonifacio M, Mosna F, Delia M, Minetto P, Gottardi M, Fracchiolla N, Mancini V, Forghieri F, Zappasodi P, Cerrano M, Vitale A, Audisio E, Trappolini S, Romani C, Defina M, Imbergamo S, Ciccone N, Santoro L, Cambò B, Iaccarino S, Dargenio M, Aprile L, Chiaretti S, Fanin R, Pizzolo G, and Foà R
- Subjects
- Adolescent, Adult, Allografts, Disease-Free Survival, Female, Follow-Up Studies, Humans, Male, Middle Aged, Nalbuphine adverse effects, Recurrence, Survival Rate, Hematopoietic Stem Cell Transplantation, Nalbuphine administration & dosage, Precursor Cell Lymphoblastic Leukemia-Lymphoma mortality, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Salvage Therapy
- Abstract
The outcome of relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/T-LBL) in adults is poor, with less than 20% of patients surviving at 5 years. Nelarabine is the only drug specifically approved for R/R T-ALL/T-LBL, but the information to support its use is based on limited available data. The aim of this observational phase four study was to provide recent additional data on the efficacy and safety of nelarabine in adults with R/R T-ALL/T-LBL and to evaluate the feasibility and outcome of allogeneic hematopoietic stem cell transplant (SCT) after salvage with nelarabine therapy. The primary endpoints were overall response rate (ORR) and overall survival (OS). Additional endpoints were safety, SCT rate and post-SCT OS. Between May 2007 and November 2018, 118 patients received nelarabine salvage therapy at 27 Italian hematology sites. The median age was 37 years (range 18-74 years), 73% were male, 77 had a diagnosis of T-ALL and 41 of T-LBL, and 65/118 (55%) had received more than two lines of therapy. The median number of nelarabine cycles was two (range 1-4); 43/118 (36%) patients had complete remission (CR), 16 had partial remission (14%) and 59 (50%) were refractory, with an ORR of 50%. The probability of OS, from the first dose of nelarabine, was 37% at 1 year with a median survival of 8 months. The OS at 1 year was significantly better for the 47 patients (40%) who underwent SCT after nelarabine salvage therapy (58% vs 22%, log-rank P < .001). The probability of OS at 2 and 5 years from SCT was 46% and 38%, respectively. Seventy-five patients (64%) experienced one or more drug-related adverse events (AE). Grade III-IV neurologic toxicities were observed in 9/118 (8%) of cases and thrombocytopenia or/and neutropenia (grade III-IV) were reported in 41% and 43% of cases, respectively. In conclusion, this is one of the largest cohorts of adult patients with R/R T-ALL/T-LBL treated in real life with nelarabine. Taking into account the poor prognosis of this patient population, nelarabine represents an effective option with an ORR of 50% and a CR rate of 36%. In addition, 40% of cases following nelarabine salvage therapy could undergo SCT with an expected OS at 2 and 5 years of 46% and 38%, respectively. The safety profile of nelarabine was acceptable with only 8% of cases showing grade III-IV neurological AE., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
4. Adipose tissue stromal vascular fraction and adipose tissue stromal vascular fraction plus platelet-rich plasma grafting: New regenerative perspectives in genital lichen sclerosus.
- Author
-
Tedesco M, Bellei B, Garelli V, Caputo S, Latini A, Giuliani M, Cota C, Chichierchia G, Romani C, Foddai ML, Cristaudo A, Morrone A, and Migliano E
- Subjects
- Adipose Tissue, Adult, Aged, Female, Genitalia, Humans, Male, Middle Aged, Platelet-Rich Plasma, Skin, Lichen Sclerosus et Atrophicus diagnosis, Lichen Sclerosus et Atrophicus therapy
- Abstract
Lichen sclerosus (LS) is a chronic relapsing, inflammatory skin disorder usually involving the anogenital region of both sexes lacking a resolutive therapy. This study compared adipose tissue derived-stromal vascular fraction (AD-SVF) and AD-SVF-enriched platelet-rich plasma (PRP) therapy in the management of genital LS patients. Additionally, in vitro evaluation of cells and growth factors contained in the injected SVF has been evaluated as possible predictive factors for treatment outcome. The study population was 40 patients diagnosed with LS who were symptomatic despite medical treatment. Patients (age 43-78 years) randomized into two groups using a 1:1 allocation ratio, were evaluated clinically and assessing dermatology life quality index (DLQI) before and 6 months after treatment. Both procedures demonstrated a strong safety profile with no complications linked to the therapy. After 6 months, both treatments allowed for a significant improvement respect to baseline. Combinatory therapy demonstrated decreased efficacy in late stage patients. No correlations have been found between clinical and biological findings. AD-SVF and AD-SVF plus PRP are safe and effective regenerative approaches for genital LS patients. Clinical results support the preferential use of combinatory therapy for early stage patients confirming a synergic effect of AD-SVF and PRP. In contrast, AD-SVF plus PRP is discouraged for late stage patients., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF
5. Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer.
- Author
-
Zanotti L, Paderno A, Piazza C, Pagan E, Bignotti E, Romani C, Bandiera E, Calza S, Del Bon F, Nicolai P, and Ravaggi A
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor metabolism, Case-Control Studies, Enzyme-Linked Immunosorbent Assay, Humans, Middle Aged, Prognosis, Prospective Studies, Serum chemistry, Carcinoma, Squamous Cell metabolism, ErbB Receptors metabolism, Mouth Neoplasms metabolism, Saliva chemistry
- Abstract
Objectives/hypothesis: Epidermal growth factor receptor (EGFR) is a type I transmembrane glycoprotein that is overexpressed in a wide variety of malignancies, including oral squamous cell carcinoma (OSCC). Our objective was to assess the EGFR diagnostic and prognostic value in OSCC by investigating its expression in serum and saliva of patients in comparison with healthy subjects., Study Design: Prospective case-control study., Methods: Serum and saliva samples were collected from a cohort of 63 treatment-naïve OSCC patients before surgery and a matched group of 60 healthy subjects. EGFR concentrations in serum and saliva were quantified by an enzyme-linked immunosorbent assay., Results: OSCC patients showed lower values of serum EGFR compared with controls (P = .0002). Conversely, saliva EGFR concentrations were higher in OSCC patients than in controls (P = .0014). Saliva EGFR levels were also increased in patients with higher T category (pT4 vs. pT <4, median 6.0 vs. 3.8 ng/mL, P = .02). Considering 9.2 ng/mL (fourth quartile) as the cutoff value, patients with higher levels of saliva EGFR had worse prognosis in terms of overall survival (P = .04). Conversely, no association was found between serum EGFR and clinical outcomes in OSCC patients., Conclusions: Saliva EGFR can be considered as a potential tumor marker for OSCC with both diagnostic and prognostic values. Serum EGFR levels, on the other hand, were lower in OSCC patients, but did not show any prognostic impact. Saliva EGFR levels are worthy of further investigation as a potential diagnostic and prognostic biomarker for OSCC., Level of Evidence: 3b. Laryngoscope, 127:E408-E414, 2017., (© 2017 The American Laryngological, Rhinological and Otological Society, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
6. Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues.
- Author
-
Bignotti E, Calza S, Tassi RA, Zanotti L, Bandiera E, Sartori E, Odicino FE, Ravaggi A, Todeschini P, and Romani C
- Subjects
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Computer Simulation, Female, Gene Expression Profiling, Humans, MicroRNAs metabolism, Middle Aged, RNA, Small Untranslated metabolism, Reference Standards, Reproducibility of Results, Sequence Analysis, RNA, Software, Gene Expression Regulation, Neoplastic, MicroRNAs genetics, Neoplasms, Cystic, Mucinous, and Serous genetics, Ovarian Neoplasms genetics, RNA, Small Untranslated genetics, Real-Time Polymerase Chain Reaction methods, Real-Time Polymerase Chain Reaction standards
- Abstract
MicroRNAs (miRNAs) belong to a family of small non-coding RNAs (sncRNAs) playing important roles in human carcinogenesis. Multiple investigations reported miRNAs aberrantly expressed in several cancers, including high-grade serous ovarian carcinoma (HGS-OvCa). Quantitative PCR is widely used in studies investigating miRNA expression and the identification of reliable endogenous controls is crucial for proper data normalization. In this study, we aimed to experimentally identify the most stable reference sncRNAs for normalization of miRNA qPCR expression data in HGS-OvCa. Eleven putative reference sncRNAs for normalization (U6, SNORD48, miR-92a-3p, let-7a-5p, SNORD61, SNORD72, SNORD68, miR-103a-3p, miR-423-3p, miR-191-5p, miR-16-5p) were analysed on a total of 75 HGS-OvCa and 30 normal tissues, using a highly specific qPCR. Both the normal tissues considered to initiate HGS-OvCa malignant transformation, namely ovary and fallopian tube epithelia, were included in our study. Stability of candidate endogenous controls was evaluated using an equivalence test and validated by geNorm and NormFinder algorithms. Combining results from the three different statistical approaches, SNORD48 emerged as stably and equivalently expressed between malignant and normal tissues. Among malignant samples, considering groups based on residual tumour, miR-191-5p was identified as the most equivalent sncRNA. On the basis of our results, we support the use of SNORD48 as best reference sncRNA for relative quantification in miRNA expression studies between HGS-OvCa and normal controls, including the first time both the normal tissues supposed to be HGS-OvCa progenitors. In addition, we recommend miR-191-5p as best reference sncRNA in miRNA expression studies with prognostic intent on HGS-OvCa tissues., (© 2016 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
- Published
- 2016
- Full Text
- View/download PDF
7. Prenatal presentation and postnatal evolution of a patient with Jansen metaphyseal dysplasia with a novel missense mutation in PTH1R.
- Author
-
Savoldi G, Izzi C, Signorelli M, Bondioni MP, Romani C, Lanzi G, Moratto D, Verdoni L, Pinotti M, Prefumo F, Superti-Furga A, and Pilotta A
- Subjects
- Adult, Bone and Bones diagnostic imaging, Bone and Bones pathology, Female, Humans, Infant, Newborn, Pregnancy, Radiography, Ultrasonography, Prenatal, Mutation, Missense, Osteochondrodysplasias diagnosis, Osteochondrodysplasias genetics, Receptor, Parathyroid Hormone, Type 1 genetics
- Abstract
Wave-shaped ribs were detected at prenatal ultrasound in a 20(+1) week female fetus. At birth, skeletal radiographs showed marked hypomineralization and suggested hypophosphatasia. However, elevated blood calcium and alkaline phosphatase excluded hypophosphatasia and raised the possibility of Jansen metaphyseal dysplasia. Molecular analysis of the PTH/PTHrP receptor gene (PTH1R) showed heterozygosity for a previously undescribed transversion variant (c.1373T>A), which predicts p.Ile458Lys. In vitro evaluation of wild type and mutant PTH/PTHrP receptors supported the pathogenic role of the p.Ile458Lys substitution, and confirmed the diagnosis of Jansen metaphyseal dysplasia. This disorder may present prenatally with wavy ribs and in the newborn with hypomineralization, and may therefore be confused with hypophosphatasia. The mottled metaphyseal lesions typically associated with this disease appear only in childhood., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
8. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
- Author
-
Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, and Bosi A
- Subjects
- Adenine Nucleotides administration & dosage, Adenine Nucleotides adverse effects, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Arabinonucleosides administration & dosage, Arabinonucleosides adverse effects, Clofarabine, Cytarabine administration & dosage, Cytarabine adverse effects, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Recurrence, Remission Induction, Treatment Outcome, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Myeloid, Acute drug therapy
- Abstract
Clofarabine has been shown to be effective in AML patients, either as single agent or, mainly, in association with intermediate dose cytarabine. Based on these reports, we conducted a preliminary study combining clofarabine and intermediate dose cytarabine in AML patients who relapsed or failed to respond to at least two induction therapies. We treated 47 patients affected by relapsed/refractory AML with a regimen including clofarabine at 22.5 mg/m(2) daily on days 1-5, followed after 3 hr by cytarabine at 1 g/m(2) daily on days 1-5. Ten patients received a further consolidation cycle with clofarabine at 22.5 mg/m(2) and cytarabine at 1 g/m(2) day 1-4. Among the 47 patients, 24/47 (51%) achieved a complete remission, 5/47 (10.5%) a partial response, 10/47 (21%) had a resistant disease, and 6/47 (13%) died of complications during the aplastic phase. The most frequent nonhematologic adverse events were vomiting, diarrhea, transient liver toxicity, febrile neutropenia, and infections microbiologically documented. Among the 24 patients who obtained a CR 13 underwent allogeneic bone marrow transplantation. In 14 patients, complete remission duration was shorter than 12 months, whereas 10 patients experienced longer complete remission duration. These very preliminary results suggest that clofarabine-cytarabine regimen is effective in this particularly poor prognosis category of patients, representing a potential "bridge" toward bone marrow transplant procedures. Safety data were consistent with previously reported salvage therapies. Further studies and a longer follow up are warranted., (Copyright © 2012 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
9. Intrathecal chemotherapy and meningeal relapses in myelomonocytic AML. A single institution experience.
- Author
-
Romani C, Di Tucci AA, Dessalvi P, Pettinau M, and Emanuele A
- Subjects
- Adult, Bone Marrow Transplantation, Combined Modality Therapy, Cytarabine administration & dosage, Daunorubicin administration & dosage, Etoposide administration & dosage, Female, Humans, Idarubicin administration & dosage, Injections, Spinal, Leukemia, Monocytic, Acute pathology, Leukemia, Monocytic, Acute surgery, Leukemia, Myeloid, Acute pathology, Leukemia, Myelomonocytic, Acute pathology, Leukemic Infiltration drug therapy, Male, Middle Aged, Mitoxantrone administration & dosage, Testis pathology, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Monocytic, Acute drug therapy, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myelomonocytic, Acute drug therapy, Leukemic Infiltration prevention & control, Meninges pathology
- Published
- 2010
- Full Text
- View/download PDF
10. Unexpected CNS localization in M2 acute myeloid leukemia: a link with past heroin addiction?
- Author
-
Romani C, Pettinau M, Dessalvi P, Murru R, and Angelucci E
- Subjects
- Central Nervous System Neoplasms pathology, Central Nervous System Neoplasms prevention & control, Cytarabine therapeutic use, Humans, Male, Middle Aged, Premedication, Central Nervous System Neoplasms etiology, Heroin Dependence complications, Leukemia, Myeloid, Acute pathology
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.